ABT vs LMAT: fair value comparison
Abbott Laboratories and LeMaitre Vascular, Inc. · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, LMAT currently sits closer to the top of our discount ranking. ABT carries the stronger quality grade.
| ABT | LMAT | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $108.33 | $103.61 |
| 12-month range | $87.78–$128.01 | $79.78–$111.76 |
| Sector rank | #40 of 113 Healthcare | #38 of 113 Healthcare |
| Quality grade | B | C+ |
| Leverage | Low | Low |
| Margin trend | Expanding | — |
| Revenue growth | Modest | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: ABT fair value analysis · LMAT fair value analysis